Palleon Pharmaceuticals is a biotech company that specializes in developing Glyco-Immune Checkpoint inhibitors for cancer treatment. Their unique Convergence Platform combines expertise in glycoscience and human immunology to create innovative approaches to cancer treatment. By targeting multiple immune cell types, their inhibitors aim to overcome resistance to current immuno-oncology agents and enable more effective combination therapies. Although their primary focus is oncology, their platform has potential applications in other areas such as infectious diseases, neurodegeneration, inflammation, and fibrosis.